Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE - VistaGen Therapeutics, Inc. | ex99-2.htm |
EX-99.1 - PRESENTATION - VistaGen Therapeutics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): December 19, 2019
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common
Stock, par value $0.001 per share
|
VTGN
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 7.01. Regulation FD Disclosure.
On December 26, 2019, VistaGen
Therapeutics, Inc. (the “Company”) began utilizing a new corporate presentation. A
copy of the updated corporate presentation is attached to this
Current Report on Form 8-K as Exhibit 99.1.
The
information in Item 7.01 of this Current Report
on Form 8-K, including the information set forth in
Exhibit 99.1, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“Exchange
Act”), nor shall Exhibit 99.1 filed herewith be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such a filing.
Item 8.01. Other Events.
On
December 19, 2019, the Company announced successful results from a
first-step, Phase 1b clinical study with healthy U.S.
military Veterans, which measured NMDAR (N-methyl-D-aspartate
receptor) target engagement of the Company's investigational
product candidate, AV-101, an oral NMDAR glycine site antagonist,
for potential treatment of suicidal ideation in Veterans. A
copy of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.2.
Item 9.01. Exhibits.
See
Exhibit Index.
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
Date:
December 27, 2019
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
|
|
|
|
VistaGen
Therapeutics, Inc. Corporate Presentation, dated December
2019.
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated December 19,
2019.
|